Combination Treatment of Murine Colon Cancer with Doxorubicin and Redox Nanoparticles

Molecular Pharmaceutics

Volumn 13, Issue 2, 2016, Pages 449-455

  Vong, Long Binh ^a   Nagasaki, Yukio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

adverse effect; chemotherapy; combination therapy; drug resistance; reactive oxygen species; redox nanotherapeutics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DOXORUBICIN; LACTATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PH INSENSITIVE REDOX NANOPARTICLE; PH SENSITIVE REDOX NANOPARTICLE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; AZOXYMETHANE; CARCINOGEN; DRUG CARRIER; NITROGEN OXIDE; NITROXYL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CELL TRANSPORT; CELL VACUOLE; COLON CANCER; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOPLASM; DRUG HALF LIFE; DRUG POTENTIATION; DRUG UPTAKE; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID OXIDATION; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; WEIGHT REDUCTION; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; COLONIC NEOPLASMS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AZOXYMETHANE; CARCINOGENS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; MALE; MICE; MICE, INBRED ICR; NANOPARTICLES; NITROGEN OXIDES; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 84957310564     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00676     Document Type: Article

References (29)

1. Tacar, O.; Sriamornsak, P.; Dass, C. R. Doxorubicin: an on update anticancer molecular action, toxicity and novel drug delivery systems J. Pharm. Pharmacol. 2013, 65 (2) 157-70 10.1111/j.2042-7158.2012.01567.x
2. 2+ increase are reciprocally modulated in rat cardiomyocytes Exp. Mol. Med. 2006, 38 (5) 535-45 10.1038/emm.2006.63
3. Shi, Y.; Moon, M.; Dawood, S.; McManus, B.; Liu, P. P. Mechanisms and management of doxorubicin cardiotoxicity Herz. 2011, 36 (4) 296-305 10.1007/s00059-011-3470-3
4. Zhang, S.; Liu, X.; Bawa-Khalfe, T.; Lu, L. S.; Lyu, Y. L.; Liu, L. F.; Yeh, E. T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat. Med. 2012, 18 (11) 1639-42 10.1038/nm.2919
5. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery 2006, 5, 219-34 10.1038/nrd1984
6. Notarbartolo, M.; Poma, P.; Perri, D.; Dusonchet, L.; Cervello, M.; D'Alessandro, N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression Cancer Lett. 2005, 224 (1) 53-65 10.1016/j.canlet.2004.10.051
7. Doroshow, J. H.; Locker, G. Y.; Ifrim, I.; Myers, C. E. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine J. Clin. Invest. 1981, 68 (4) 1053-64 10.1172/JCI110328
8. Brookins Danz, E. D.; Skramsted, J.; Henry, N.; Bennett, J. A.; Keller, R. S. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway Free Radical Biol. Med. 2009, 46, 1589-97 10.1016/j.freeradbiomed.2009.03.011
9. Yoshitomi, T.; Miyamoto, D.; Nagasaki, Y. Design of core-shell-type nanoparticles carrying stable radicals in the core Biomacromolecules 2009, 10 (3) 596-601 10.1021/bm801278n
10. Yoshitomi, T.; Suzuki, R.; Mamiya, T.; Matsui, H.; Hirayama, A.; Nagasaki, Y. pH-sensitive radical-containing-nanoparticle (RNP) for the L-band-EPR imaging of low pH circumstances Bioconjugate Chem. 2009, 20 (9) 1792-8 10.1021/bc900214f
11. Yoshitomi, T.; Hirayama, A.; Nagasaki, Y. The ROS scavenging and renal protective effects of pH-responsive nitroxide radical-containing nanoparticles Biomaterials 2011, 32, 8021-8 10.1016/j.biomaterials.2011.07.014
12. Chonpathompikunlert, P.; Fan, C. H.; Ozaki, Y.; Yoshitomi, T.; Yeh, C. K.; Nagasaki, Y. Redox nanoparticle treatment protects against neurological deficit in focused ultrasound-induced intracerebral hemorrhage Nanomedicine 2012, 7 (7) 1029-43 10.2217/nnm.12.2
13. Marushima, A.; Suzuki, K.; Nagasaki, Y.; Yoshitomi, T.; Toh, K.; Tsurushima, H.; Hirayama, A.; Matsumura, A. Newly synthesized radical-containing nanoparticles (RNP) enhance neuroprotection after cerebral ischemia-reperfusion injury Neurosurgery 2011, 68 (5) 1418-26 10.1227/NEU.0b013e31820c02d9
14. Yoshitomi, T.; Ozaki, Y.; Thangavel, S.; Nagasaki, Y. Redox nanoparticle therapeutics to cancer - increase in therapeutic effect of doxorubicin, suppressing its adverse effect J. Controlled Release 2013, 172 (1) 137-43 10.1016/j.jconrel.2013.08.011
15. Vong, L. B.; Tomita, T.; Yoshitomi, T.; Matsui, H.; Nagasaki, Y. An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice Gastroenterology 2012, 143 (4) 1027-36 10.1053/j.gastro.2012.06.043
16. Vong, L. B.; Mo, J.; Abrahamsson, B.; Nagasaki, Y. Specific accumulation of orally administered redox nanotherapeutics in the inflamed colon reducing inflammation with dose-response efficacy J. Controlled Release 2015, 210, 19-25 10.1016/j.jconrel.2015.05.275
17. Vong, L. B.; Yoshitomi, T.; Matsui, H.; Nagasaki, Y. Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer Biomaterials 2015, 55, 54-63 10.1016/j.biomaterials.2015.03.037
18. Kim, J.; Jung, K. J.; Park, K. M. Reactive oxygen species differently regulate renal tubular epithelial and interstitial cell proliferation after ischemia and reperfusion injury Am. J. Physiol. Renal Physiol. 2010, 298, F1118-29 10.1152/ajprenal.00701.2009
19. Wang, X.; Fang, H.; Huang, Z.; Shang, W.; Hou, T.; Cheng, A.; Cheng, H. Imaging ROS signaling in cells and animals J. Mol. Med. (Heidelberg, Ger.) 2013, 91 (8) 917-27 10.1007/s00109-013-1067-4
20. Becker, C.; Fantini, M. C.; Neurath, M. F. High resolution colonoscopy in live mice Nat. Protoc. 2007, 1, 2900-4 10.1038/nprot.2006.446
21. Yoshitomi, T.; Yamaguchi, Y.; Kikuchi, A.; Nagasaki, Y. Creation of a blood-compatible surface: A novel strategy for suppressing blood activation and coagulation using a nitroxide radical-containing polymer with reactive oxygen species scavenging activity Acta Biomater. 2012, 8 (3) 1323-9 10.1016/j.actbio.2011.11.029
22. Yoshitomi, T.; Nagasaki, Y. Design and preparation of a nanoprobe for imaging inflammation sites Biointerphases 2012, 7, 1 10.1007/s13758-011-0007-5
23. Kaczmarek, A.; Brinkman, B. M.; Heyndrickx, L.; Vandenabeele, P.; Krysko, D. V. Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways J. Pathol. 2012, 226 (4) 598-608 10.1002/path.3009
24. Morelli, D.; Ménard, S.; Colnaghi, M. I.; Balsari, A. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice Cancer Res. 1996, 56 (9) 2082-5
25. 2- and p53-dependent pathways J. Biol. Chem. 2004, 279 (24) 25535-43 10.1074/jbc.M400944200
26. Singal, P. K.; Iliskovic, N. Doxorubicin-induced cardiomyopathy N. Engl. J. Med. 1998, 339, 900-5 10.1056/NEJM199809243391307
27. Shimizu, M.; Yoshitomi, T.; Nagasaki, Y. The behavior of ROS-scavenging nanoparticles in blood J. Clin. Biochem. Nutr. 2014, 54 (3) 166-73 10.3164/jcbn.13-85
28. Chen, J. Reactive Oxygen Species and Drug Resistance in Cancer Chemotherapy Austin J. Clin. Pathol. 2014, 1 (4) 1017
29. Hong, H.; Lu, Y.; Ji, Z. N.; Liu, G. Q. Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells J. Neurochem. 2006, 98 (5) 1465-73 10.1111/j.1471-4159.2006.03993.x